Ketamine clinic statistics
Ketamine clinic statistics for 2026, from Spravato rates to patient searches
29 figures on patients, clinics, advertising, Spravato, trials, rules and search demand, each linked to the document that published it. Most were read at source on November 9, 2026.
Get the ketamine AI answer sheetPatients
How many adults live with depression, and how many have tried treatment
National estimates from SAMHSA’s 2024 household survey, and one claims-based count of treatment-resistant depression.
| Figure | What it measures | Source |
|---|---|---|
| 21.4 million | Adults in the US with a major depressive episode in the past year, 8.2% of all adults, in 2024 | SAMHSA, 2024 National Survey on Drug Use and Health, released July 28, 2025 |
| 14.7 million | Adults whose past-year episode came with severe impairment in 2024, or 5.6% of adults | SAMHSA, 2024 National Survey on Drug Use and Health, released July 28, 2025 |
| 64.4% | Adults with a past-year major depressive episode who received any mental health treatment during 2024 | SAMHSA, 2024 National Survey on Drug Use and Health, released July 28, 2025 |
| 2.8 million | Adults with treatment-resistant depression in a 12-month period: 30.9% of the 8.9 million whose major depressive disorder was treated with medication | Zhdanava and colleagues (Analysis Group and Janssen researchers), Journal of Clinical Psychiatry, March 16, 2021 |
Treatment-resistant depression is the condition Spravato is approved to treat. None of these four figures counts ketamine patients.
Clinics
Who runs the clinics, and what they offer beyond the infusion chair
One national survey with a website review, and one count of clinics advertising around New York.
| Figure | What it measures | Source |
|---|---|---|
| 484 | Community clinics offering ketamine with a public email address, drawn from four clinic databases and surveyed September to November 2023; 119 replies were analyzed | Pacilio, Parikh and Geller, Journal of Clinical Psychiatry, May 26, 2025 |
| Under 30% | Share of 473 clinic websites, read by the same researchers in June 2024, that showed psychiatric physicians running the clinic; nonphysician providers ran over 25% | Pacilio, Parikh and Geller, Journal of Clinical Psychiatry, May 26, 2025 |
| Over 80% | Surveyed clinics that use maintenance ketamine treatment; over 40% supplied ketamine to take at home | Pacilio, Parikh and Geller, Journal of Clinical Psychiatry, May 26, 2025 |
| 36.5% | Clinics that prescribed ketamine for home use, of 233 found advertising it for psychiatric conditions in the New York metropolitan area in 2025 | Abukahok and colleagues, Fundamental & Clinical Pharmacology, July 2026 |
| 94.0% | Those 233 clinics that listed depression among the disorders they treat; 21.9% advertised ketamine for substance use disorder, and 51.5% listed a medical doctor | Abukahok and colleagues, Fundamental & Clinical Pharmacology, July 2026 |
The 484 is the survey’s frame, the clinics researchers could email. It is not a census of US clinics, and no census exists.
Advertising and price
What Maryland’s ketamine ads left out, and what an infusion cost
All 17 ketamine advertisers the researchers found operating in Maryland in March 2023, read for claims and prices.
| Figure | What it measures | Source |
|---|---|---|
| 58.8% | Advertisers, 10 of the 17, whose ads never disclosed that the ketamine treatment offered was off-label | Crane, DiStefano and Moore, JAMA Network Open, November 1, 2023 |
| 41.1% | Advertisers, 7 of the 17, naming no risk at all of adverse effects, addiction or misuse; 3 called ketamine nonaddictive and 1 claimed FDA approval for depression, both false | Crane, DiStefano and Moore, JAMA Network Open, November 1, 2023 |
| $360 to $2,500 | Listed price of a single infusion, among the 7 of 13 infusion advertisers that put a price online | Crane, DiStefano and Moore, JAMA Network Open, November 1, 2023 |
One state in one month. The price range is what those seven clinics listed, not a national average.
Evidence and Spravato
Trial results a page may quote, and how Spravato is given and paid
Two trials with their populations named, then Spravato’s approval, monitoring and Medicare payment.
| Figure | What it measures | Source |
|---|---|---|
| 55.4% vs 41.2% | Patients who responded by three weeks in the ELEKT-D trial, IV ketamine against ECT, among 403 adults with nonpsychotic treatment-resistant depression referred for ECT; self-reported scale | Anand and colleagues, New England Journal of Medicine, June 22, 2023 |
| 4.0 points | Gap on the 60-point MADRS after four weeks in Spravato’s Study 1 of 223 adults aged 18 to 64 with treatment-resistant depression: scores fell 19.8 points on Spravato with an antidepressant, 15.8 on placebo with one | Spravato prescribing information, label version 21 on DailyMed, September 24, 2026, section 14.1 |
| March 5, 2019 | First FDA approval of Spravato and its REMS; use on its own, without an oral antidepressant, for treatment-resistant depression followed in January 2025 | FDA approval letters for NDA 211243, supplements S-016 and S-027 |
| 2 hours | Minimum monitoring at each Spravato session, pulse oximetry included, in a REMS-certified setting | Spravato prescribing information, label version 21 on DailyMed, September 24, 2026 |
| $1,356.08 | Medicare’s 2026 national amount for a Spravato visit above 56 mg (HCPCS G2083), esketamine and two hours of observation included, before geographic adjustment | CMS fee schedule file RVU26D, August 26, 2026: 40.60 RVUs times $33.4009, multiplied by Webzenia |
| $952.59 | The same national amount for a visit of 56 mg or less (HCPCS G2082) | CMS fee schedule file RVU26D, August 26, 2026: 28.52 RVUs times $33.4009, multiplied by Webzenia |
ELEKT-D compared IV ketamine with ECT, not with an antidepressant, and its patients had already been referred for ECT.
Rules and enforcement
Dates, fees and settlements that bear on a clinic’s marketing
Each figure comes from the rule, the order or the fee schedule itself.
| Figure | What it measures | Source |
|---|---|---|
| December 31, 2026 | End of the DEA flexibility for prescribing controlled substances, ketamine among them, by telemedicine with no in-person evaluation; no extension had been published by November 9, 2026 | DEA rule at 21 CFR 1307.41, extended by 90 FR 61301, Federal Register, December 31, 2025 |
| July 1, 2027 | Date from which Georgia requires any clinic giving IV ketamine to hold a license from its medical board, under HB 717, signed May 12, 2026 | Georgia General Assembly, HB 717 (Act 634), 2026 session |
| June 23, 2026 | Date of an FDA warning letter to a website selling unapproved and misbranded ketamine lozenges to US consumers | FDA warning letter MARCS-CMS 725148, June 23, 2026 |
| Over $7 million | What online mental health company Cerebral agreed to pay in April 2024 to settle FTC charges, among them passing the health data of nearly 3.2 million consumers to advertisers through tracking tools | FTC press release on the proposed Cerebral order, April 15, 2024, read through an archived copy |
| $30,000 | Settlement paid in 2023 by a New Jersey psychiatry practice whose replies to bad online reviews disclosed patients’ information | HHS Office for Civil Rights announcement, June 5, 2023, from our healthcare research record |
| $182,000 | Settlement HHS reached in 2025 with a provider whose website published 150 patients’ success stories with no signed authorization | HHS Office for Civil Rights announcement, September 30, 2025, from our healthcare research record |
| $3,125 | First-year LegitScript cost for one website, $975 to apply and $2,150 a year; Google asks it of telemedicine providers and addiction services, Meta of telehealth providers promoting prescription drugs | LegitScript, healthcare certification price page, no date shown |
A settlement is an agreement, not a court finding. The DEA date and Georgia’s board rules, due by December 31, 2026, are the two figures here most likely to change.
Search demand
What patients search for, and how rarely ads appear
US monthly volumes from Semrush; the two shares are summed across 10,503 searches by Webzenia.
| Figure | What it measures | Source |
|---|---|---|
| 110,000 | US searches a month for “ketamine therapy” | US keyword volumes from Semrush’s Keyword Magic Tool, October 10, 2026 pull |
| 60.8% | Share of monthly patient search volume for ketamine therapy and clinic terms, 349,920 searches in all, on which Google showed an AI Overview | Semrush US database, October 10, 2026, SERP features summed by Webzenia |
| 1.1% | Share of that same patient search volume on which Semrush recorded any ad at all | Semrush US database, October 10, 2026, SERP features summed by Webzenia |
| 210 | US searches a month by clinic owners for “ketamine clinic marketing”, with no measured cost per click | US keyword volumes from Semrush’s Keyword Magic Tool, October 10, 2026 pull |
How the figures were chosen
What made this page, and what was kept off it
A figure appears only when its publisher could be read directly and it says no more than that publisher did.
Included
- Peer-reviewed studies, with each study’s population and dates in the row
- FDA, DEA, CMS and HHS documents, quoted at the strength of the document
- Spravato figures and IV ketamine figures in separate rows
- Semrush counts, labeled with the pull date and Webzenia’s method
Left out
- Clinic counts and market sizes that name no source or come from paid reports
- Price roundups from treatment directories whose method is not stated
- Texas’s proposed ketamine infusion rule, which had not been adopted
- State bills we could not confirm at their official source
Questions
What the ketamine figures answer, and what they leave open
Short answers, each tied to a row above.
Start here
Put your own consults and treatment starts beside these figures
Name your offices and the treatments each one gives. We ask AI engines the questions patients ask about IV ketamine and Spravato in your metro, and send a dated sheet of the clinics they name.